Yahoo Finance

• Cash, Cash Equivalents, and Marketable Securities: $38.5 million as of June 30, 2024.

• Revenue: $1.4 million, a decrease from $3.2 million in the same period in 2023.

• Total Operating Expenses: $7.3 million, a decrease from $8.2 million in the same period in 2023.

• Research and Development Expenses: $2.9 million, a decrease from $3.9 million in the same period in 2023.

• General and Administrative Expenses: $4.3 million, an increase from $4.2 million in the same period in 2023.

• Loss from Operations: $5.9 million, an increase from $5 million in the same period in 2023.

• Net Loss: $5.8 million, or $0.03 per share, compared to a net loss of $5.2 million, or $0.03 per share, in the same period in 2023.

• Other Income: $0.1 million, compared to other expenses of ($0.2) million in the same period in 2023.

• Warning! GuruFocus has detected 4 Warning Signs with LCTX.

Release Date: August 08, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Lineage Cell Therapeutics Inc (LCTX) has successfully expanded its alliance with Roche and Genentech, reflecting positive developments in their OpRegen program.

• The company has opened its first ex-US clinical site for the OpRegen Phase 2 trial in Israel, enhancing the program's global reach.

• Lineage Cell Therapeutics Inc (LCTX) has a strong cash position with $38.5 million in cash, cash equivalents, and marketable securities, expected to support operations into Q4 2025.

• The company is making strategic investments in its pipeline, including promising preclinical programs like ANP1 for hearing loss and a new undisclosed neurology program.

• Lineage Cell Therapeutics Inc (LCTX) maintains a disciplined approach to fiscal management, allowing it to navigate the challenging biotech market environment effectively.

Negative Points

• The biotech sector remains in a prolonged bear market, affecting investor sentiment and capital availability for Lineage Cell Therapeutics Inc (LCTX).

• The company experienced a decrease in total revenues to $1.4 million, down from $3.2 million in the same period in 2023, primarily due to lower collaboration and licensing revenues.

• Lineage Cell Therapeutics Inc (LCTX) is facing delays in FDA review for its IND amendment related to the OPC1 program, impacting the timeline for initiating the DOSED study.

• The company reported a net loss of $5.8 million for the quarter, an increase from the $5.2 million loss in the same period in 2023.

• There is uncertainty regarding the timing and availability of clinical data from the OpRegen trial, as Lineage does not control the release of this information.